Skip to content Skip to footer
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) delivered the sort of update growth investors prefer: higher guidance, record revenue, expanding treatment access, and a more visible route toward operating leverage. Shares climbed sharply after the company lifted its 2026 revenue outlook, suggesting Wall Street is…
New York’s lawsuit against Polymarket U.S. is an obvious legal headache, but it may also accelerate the industry’s most valuable long-term asset: a clearer rulebook. For investors, operators, exchanges and market-infrastructure companies, the real story is not whether prediction markets face scrutiny,…
Many entered the week bracing for a Federal Reserve rate hike, yet the more constructive takeaway may be that policy makers still have room to choose patience. That possibility, alongside fresh evidence of AI-led ecommerce change, government-scale digital-health demand and advancing biotech milestones,…
Artificial intelligence is rapidly becoming the world’s next great infrastructure project, part semiconductor cycle, part energy transition, part national-security exercise. PwC now estimates cumulative AI-infrastructure investment could reach $31.6 trillion by 2050, creating a long-duration opportunity set that stretches well beyond the familiar…